eucalyptus
发表于 2025-3-23 09:47:16
http://reply.papertrans.cn/19/1884/188311/188311_11.png
fleeting
发表于 2025-3-23 16:30:46
http://reply.papertrans.cn/19/1884/188311/188311_12.png
过滤
发表于 2025-3-23 19:13:23
Sven Agten,Ben WuExplores legal issues around medicine in China.Examines the growing biopharma industry in China.Offers insights for professionals
Paleontology
发表于 2025-3-24 00:15:51
http://reply.papertrans.cn/19/1884/188311/188311_14.png
Intersect
发表于 2025-3-24 06:04:22
http://reply.papertrans.cn/19/1884/188311/188311_15.png
senile-dementia
发表于 2025-3-24 08:03:01
http://reply.papertrans.cn/19/1884/188311/188311_16.png
抵押贷款
发表于 2025-3-24 12:44:56
http://reply.papertrans.cn/19/1884/188311/188311_17.png
在前面
发表于 2025-3-24 18:28:29
http://reply.papertrans.cn/19/1884/188311/188311_18.png
诱导
发表于 2025-3-24 21:00:28
http://reply.papertrans.cn/19/1884/188311/188311_19.png
B-cell
发表于 2025-3-25 02:29:28
Innovation in the Chinese Biopharma Sector: From Me-too to First-in-Class,eld of antibodies. Learning from past experiences and urged on by their investors, since 2020 an increasing number of Chinese biopharmas have embarked on a strategy to develop first-in-class drugs with global potential using novel technologies. Especially during the pandemic, China became host to a